{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:39Z","timestamp":1794011439945,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["V435824N"],"award-info":[{"award-number":["V435824N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S68523N"],"award-info":[{"award-number":["1S68523N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S55619N"],"award-info":[{"award-number":["1S55619N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","award":["KOTK_VUB\/2024\/13879"],"award-info":[{"award-number":["KOTK_VUB\/2024\/13879"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese scolarship counsil"},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["strategic research program (SRP84)"],"award-info":[{"award-number":["strategic research program (SRP84)"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["strategic research program (SRP84)"],"award-info":[{"award-number":["strategic research program (SRP84)"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["strategic research program (SRP84)"],"award-info":[{"award-number":["strategic research program (SRP84)"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["strategic research program (SRP84)"],"award-info":[{"award-number":["strategic research program (SRP84)"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["strategic research program (SRP84)"],"award-info":[{"award-number":["strategic research program (SRP84)"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","award":["2022-J1811380-E003"],"award-info":[{"award-number":["2022-J1811380-E003"]}],"id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","award":["2022-J1811380-E003"],"award-info":[{"award-number":["2022-J1811380-E003"]}],"id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","award":["2022-J1811380-E003"],"award-info":[{"award-number":["2022-J1811380-E003"]}],"id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2024-165_F2530"],"award-info":[{"award-number":["2024-165_F2530"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2024-165_F2530"],"award-info":[{"award-number":["2024-165_F2530"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01756-5","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:45:55Z","timestamp":1763138755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA\/B7-H3 CAR T cells overcome antigen escape"],"prefix":"10.1186","volume":"18","author":[{"given":"Arne","family":"Van der Vreken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"van den Broecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Vescovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenja","family":"Watt\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Autaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Marco","family":"Aragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Billiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"De Vlaeminck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Breckpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"1","key":"1756_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1756_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"1756_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling cars: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"1756_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"Supplement1","key":"1756_CR5","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1182\/blood-2019-129088","volume":"134","author":"L Mikkilineni","year":"2019","unstructured":"Mikkilineni L, Manasanch EE, Lam N, Vanasse D, Brudno JN, Maric I, et al. T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor with a fully-human heavy-chain-only antigen recognition domain induce remissions in patients with relapsed multiple myeloma. Blood. 2019;134(Supplement1):3230\u20133230.","journal-title":"Blood"},{"issue":"22","key":"1756_CR6","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N. T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1756_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00716-3","volume":"12","author":"H Chen","year":"2022","unstructured":"Chen H, Yu T, Lin L, Xing L, Cho SF, Wen K, et al. \u0393-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12(8):118.","journal-title":"Blood Cancer J"},{"issue":"7","key":"1756_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, et al. \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811\u201322.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1756_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad \u00d8, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43.","journal-title":"Mol Cancer"},{"issue":"11","key":"1756_CR10","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/s41379-020-0587-z","volume":"33","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zhao ZX, Cheng P, Huang F, Guan X, Zhang MG, et al. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. Mod Pathol. 2020;33(11):2330\u201340.","journal-title":"Mod Pathol"},{"key":"1756_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759528","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Cai Q, Shen X, Chen X, Guan Z. Overexpression of B7-H3 is associated with poor prognosis in laryngeal cancer. Front Oncol. 2021;11:759528. https:\/\/doi.org\/10.3389\/fonc.2021.759528","journal-title":"Front Oncol"},{"issue":"8","key":"1756_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/cr.2017.90","volume":"27","author":"Yhee Lee","year":"2017","unstructured":"Lee Yhee, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034\u201345.","journal-title":"Cell Res"},{"issue":"6","key":"1756_CR13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","volume":"33","author":"L Lin","year":"2019","unstructured":"Lin L, Cao L, Liu Y, Wang K, Zhang X, Qin X, et al. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3. Leukemia. 2019;33(6):1475\u201386.","journal-title":"Leukemia"},{"issue":"5","key":"1756_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227\u201335.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1756_CR15","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","volume":"113","author":"D Hose","year":"2009","unstructured":"Hose D, R\u00e8me T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of Aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18):4331\u201340.","journal-title":"Blood"},{"issue":"4","key":"1756_CR16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109(4):1692\u2013700.","journal-title":"Blood"},{"issue":"4","key":"1756_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010673","volume":"13","author":"A Van der Vreken","year":"2025","unstructured":"Van der Vreken A, Thery F, Tu C, Mwangi K, Meulewaeter S, De Beck L, et al. Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy. J Immunother Cancer. 2025;13(4):e010673.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1756_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009110","volume":"12","author":"F Meeus","year":"2024","unstructured":"Meeus F, Funeh CN, Awad RM, Zeven K, Autaers D, De Becker A, et al. Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity. J Immunother Cancer. 2024;12(11):e009110.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1756_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/leu.2013.292","volume":"28","author":"M Lemaire","year":"2014","unstructured":"Lemaire M, D\u2019Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies. Leukemia. 2014;28(2):444\u20137.","journal-title":"Leukemia"},{"key":"1756_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1389018","volume":"15","author":"H Hanssens","year":"2024","unstructured":"Hanssens H, Meeus F, De Vlaeminck Y, Lecocq Q, Puttemans J, Debie P, et al. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization. Front Immunol. 2024;15:1389018. https:\/\/doi.org\/10.3389\/fimmu.2024.1389018","journal-title":"Front Immunol"},{"key":"1756_CR21","doi-asserted-by":"crossref","unstructured":"De Vlaeminck Y, De, Bonelli S, Awad RM, Dewilde M, Rizzolio S, Lecocq Q et al. Targeting Neuropilin-1 with nanobodies reduces colorectal carcinoma development. Cancers (Basel). 2020;12(12):3582.","DOI":"10.3390\/cancers12123582"},{"issue":"1","key":"1756_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","volume":"33","author":"M Bachiller","year":"2025","unstructured":"Bachiller M, Barcel\u00f3-Genestar N, Rodriguez-Garcia A, Alserawan L, Doba\u00f1o-L\u00f3pez C, Gim\u00e9nez-Alejandre M, et al. ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma. Mol Ther. 2025;33(1):317\u201335.","journal-title":"Mol Ther"},{"issue":"2","key":"1756_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/path.6066","volume":"260","author":"A Van der Vreken","year":"2023","unstructured":"Van der Vreken A, Oudaert I, Ates G, Faict S, Vlummens P, Satilmis H, et al. Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis. J Pathol. 2023;260(2):112\u201323.","journal-title":"J Pathol"},{"issue":"25","key":"1756_CR24","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee H, Durante M, Skerget S, Vishwamitra D, Benaoudia S, Ahn S, et al. Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood. 2024;144(25):2637\u201351.","journal-title":"Blood"},{"issue":"7","key":"1756_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato JM, Edwards JP, Zaritskaya L, Witter AR, Gupta A, LaFleur DW, et al. Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain. Mol Cancer Ther. 2022;21(7):1171\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1756_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15(1):615.","journal-title":"Nat Commun"},{"issue":"1","key":"1756_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43416-7","volume":"14","author":"RC Larson","year":"2023","unstructured":"Larson RC, Kann MC, Graham C, Mount CW, Castano AP, Lee WH, et al. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat Commun. 2023;14(1):7509.","journal-title":"Nat Commun"},{"issue":"1","key":"1756_CR28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/med.21818","volume":"42","author":"H Hanssens","year":"2022","unstructured":"Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. The antigen-binding moiety in the driver\u2019s seat of cars. Med Res Rev. 2022;42(1):306\u201342.","journal-title":"Med Res Rev"},{"key":"1756_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111239","volume":"126","author":"J Zhou","year":"2024","unstructured":"Zhou J, Shi F, Luo X, Lei B, Shi Z, Huang C, et al. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR. Int Immunopharmacol. 2024;126:111239.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1756_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40303-z","volume":"14","author":"T Sar\u00e9n","year":"2023","unstructured":"Sar\u00e9n T, Saronio G, Marti Torrell P, Zhu X, Thelander J, Andersson Y, et al. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nat Commun. 2023;14(1):4732.","journal-title":"Nat Commun"},{"issue":"1","key":"1756_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):164.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1756_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"1756_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"6","key":"1756_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"key":"1756_CR35","doi-asserted-by":"crossref","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","DOI":"10.1038\/s41571-019-0184-6"},{"issue":"9","key":"1756_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"6","key":"1756_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006699","volume":"11","author":"L Lee","year":"2023","unstructured":"Lee L, Lim WC, Galas-Filipowicz D, Fung K, Taylor J, Patel D, et al. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. J Immunother Cancer. 2023;11(6):e006699.","journal-title":"J Immunother Cancer"},{"key":"1756_CR38","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S2152-2650(23)01591-4","volume":"23","author":"L Rasche","year":"2023","unstructured":"Rasche L, Truger M, Munawar U, Helal M, Han S, Zhou X, et al. OA-24 sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing. Clin Lymphoma Myeloma Leuk. 2023;23:S15.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1756_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03022-x","volume":"43","author":"HW Lee","year":"2024","unstructured":"Lee HW, O\u2019Reilly C, Beckett AN, Currier DG, Chen T, DeRenzo C. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKC\u03b1 activation. J Exp Clin Cancer Res. 2024;43(1):97.","journal-title":"J Exp Clin Cancer Res"},{"key":"1756_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023;15:eadf6732. https:\/\/doi.org\/10.1126\/scitranslmed.adf6732.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1756_CR41","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.18632\/oncotarget.1821","volume":"5","author":"K Maes","year":"2014","unstructured":"Maes K, Smedt E, De, Lemaire M, Raeve H, De ME, Van Valckenborgh E, et al. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget. 2014;5(10):3115\u201329.","journal-title":"Oncotarget"},{"issue":"5","key":"1756_CR42","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.18632\/oncotarget.3207","volume":"6","author":"K Maes","year":"2015","unstructured":"Maes K, De Smedt E, Kassambara A, Hose D, Seckinger A, Van Valckenborgh E, et al. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget. 2015;6(5):3319\u201334.","journal-title":"Oncotarget"},{"issue":"1","key":"1756_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12(1):409.","journal-title":"Nat Commun"},{"issue":"1","key":"1756_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36881-7","volume":"14","author":"HJ Liu","year":"2023","unstructured":"Liu HJ, Du H, Khabibullin D, Zarei M, Wei K, Freeman GJ, et al. mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion. Nat Commun. 2023;14(1):1214.","journal-title":"Nat Commun"},{"key":"1756_CR45","doi-asserted-by":"crossref","unstructured":"Wang Y, Muylaert C, Wyns A, Vlummens P, De Veirman K, Vanderkerken K et al. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma. Haematologica. 2024;109(1):256\u201371.","DOI":"10.3324\/haematol.2023.282866"},{"issue":"1","key":"1756_CR46","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic Pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 2023;13(1):114\u201331.","journal-title":"Cancer Discov"},{"issue":"35","key":"1756_CR47","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, et al. STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors. J Clin Oncol. 2024;42(35):4163\u201372.","journal-title":"J Clin Oncol"},{"key":"1756_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.956593","volume":"12","author":"G Hu","year":"2022","unstructured":"Hu G, Li G, Wen W, Ding W, Zhou Z, Zheng Y, et al. Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient. Front Oncol. 2022;12:956593. https:\/\/doi.org\/10.3389\/fonc.2022.956593.","journal-title":"Front Oncol"},{"issue":"6","key":"1756_CR49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"11","key":"1756_CR50","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","volume":"27","author":"EI Lichtman","year":"2021","unstructured":"Lichtman EI, Du H, Shou P, Song F, Suzuki K, Ahn S, et al. Preclinical evaluation of B7-H3-specific chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Clin Cancer Res. 2021;27(11):3141\u201353.","journal-title":"Clin Cancer Res"},{"key":"1756_CR51","first-page":"144","volume":"26","author":"N Ho","year":"2022","unstructured":"Ho N, Agarwal S, Milani M, Cantore A, Buchholz CJ, Thalheimer FB. In vivo generation of CAR T cells in the presence of human myeloid cells. Mol Ther. 2022;26:144\u201356.","journal-title":"Mol Ther"},{"issue":"3","key":"1756_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102676","volume":"36","author":"OK Dagher","year":"2025","unstructured":"Dagher OK, Pedard M, Bedoya DM, Brookens SK, Migliorini D, Posey AD. Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma. Mol Ther Nucleic Acids. 2025;36(3):102676.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"18","key":"1756_CR53","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"key":"1756_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1391954","volume":"15","author":"SJ Holzmayer","year":"2024","unstructured":"Holzmayer SJ, Liebel K, Hagelstein I, Salih HR, M\u00e4rklin M. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas. Front Immunol. 2024;15:1391954. https:\/\/doi.org\/10.3389\/fimmu.2024.1391954.","journal-title":"Front Immunol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01756-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T02:02:59Z","timestamp":1763172179000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01756-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1756"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01756-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Procedures in mice were performed within the ethical framework of the Belgian law and approved by the Ethical Committee for use of Laboratory Animals of the VUB (24-281-2). Ethical approval and informed consent for peripheral blood mononuclear cell collection from healthy donors, and ethical approval and informed consent for bone marrow (BM) aspirates from multiple myeloma (MM) patients were obtained from the Medical Ethical Committee of the university hospital (UZ) Brussel (1432023000220 and 143201838414, respectively). All samples were anonymized by the UZ Brussel biobank. Ethical approval and informed consent for BM aspirates of MM patients at the Department of Medicine and Surgery of the University of Parma were obtained by its Institutional Review Boards and were anonymized in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}